Skip to main content

Table 2 Secondary endpoints at Week 13 (double-blind treatment period; LOCF analysis)

From: Efficacy and safety of duloxetine versus placebo in adolescents with juvenile fibromyalgia: results from a randomized controlled trial

 

LS means for change from baseline (SE)

double-blind treatment period

Open-label treatment period

Acute + Open-label

Placebo (n = 93)

Duloxetine (n = 91)

Treatment difference

p-value

Placebo/duloxetine (n = 75)

Duloxetine/duloxetine (n = 74)

All patients randomized to duloxetine (n = 90)a

BPI Severity and Interference Ratings

 Worst pain score

−0.96 (0.267)

−1.43 (0.275)

− 0.47

0.175

− 0.8 (0.256)**

− 0.65 (0.262)*

− 1.66 (0.342)**

 Least pain score

− 0.60 (0.242)

− 0.96 (0.247)

− 0.35

0.255

− 0.45 (0.212)*

−0.29 (0.218)

− 0.86 (0.267)**

 Pain score right now

− 1.17 (0.270)

− 1.44 (0.276)

− 0.26

0.446

− 0.29 (0.252)

− 0.38 (0.259)

−1.31 (0.312)**

Incidence of Treatment Responseb, n (%)

  ≥30% Reduction

33 (36.26)

47 (52.22)

0.032†

27 (37.50)

25 (36.23)

49 (54.44)

  ≥50% Reduction

22 (24.18)

36 (40.00)

0.029†

18 (25.00)

17 (24.64)

44 (48.89)

BPI interference

 General activity

−0.99 (0.273)

−1.75 (0.280)

− 0.76

< 0.030*

− 0.20 (0.229)

− 0.18 (0.233)

− 1.74 (0.316)**

 Mood

− 1.54 (0.273)

− 1.97 (0.279)

−0.43

0.220

−0.25 (0.258)

− 0.15 (0.270)

−1.59 (0.330)**

 Walking ability

−1.21 (0.266)

−1.20 (0.271)

0.01

0.966

−0.21 (0.253)

−0.24 (0.260)

− 0.92 (0.285)**

 Normal work

−1.19 (0.281)

−1.41 (0.286)

− 0.22

0.545

−0.32 (0.226)

− 0.62 (0.231)**

− 1.69 (0.328)**

 Relations with other people

− 1.07 (0.236)

− 1.83 (0.241)

− 0.77

0.013*

− 0.41 (0.222)

− 0.12 (0.229)

−1.53 (0.264)**

 Sleep

−1.16 (0.344)

−1.28 (0.352)

−0.12

0.788

−0.54 (0.284)

− 0.63 (0.292)*

− 1.67 (0.417)**

 Enjoyment of life

−1.51 (0.251)

− 1.83 (0.257)

−0.32

0.320

−0.26 (0.236)

− 0.25 (0.243)

− 1.76 (0.288)**

 School work

− 1.00 (0.324)

−1.48 (0.330)

− 0.49

0.243

−0.06 (0.271)

− 0.59 (0.278)*

− 1.94 (0.362)**

BPI average interference score

− 1.21 (0.217)

− 1.60 (0.221)

−0.39

0.165

−0.32 (0.187)

− 0.30 (0.192)

−1.61 (0.264)**

PPQ score

 Average pain score

−9.41 (2.946)

−11.03 (2.982)

−1.62

0.669

−6.44 (3.296)

−10.65 (3.080)**

− 18.01 (3.523)**

 Worst pain score

−8.46 (3.322)

−14.36 (3.367)

−5.90

0.169

−8.06 (3.677)*

−4.15 (3.427)

−15.96 (3.954)**

 Pain score right now

−7.20 (3.065)

−8.99 (3.092)

−1.79

0.647

−6.34 (3.335)

−4.74 (3.075)

−8.40 (3.441)*

CGI-S: Score

 Overall

−0.66 (0.118)

−0.88 (0.121)

− 0.22

0.146

− 0.67 (0.121)**

−0.67 (0.125)**

−1.25 (0.145)**

 Mental Illness

−0.15 (0.087)

−0.16 (0.089)

− 0.01

0.927

− 0.24 (0.101)*

−0.20 (0.104)

− 0.27 (0.127)*

FDI total score

 Child total score

−5.00 (1.021)

−3.97 (1.038)

1.03

0.431

−1.03 (1.267)

−1.71 (1.202)

−5.02 (1.176)**

 Parent total score

−4.17 (1.139)

−3.25 (1.152)

0.92

0.529

−2.27 (1.327)

−3.49 (1.227)**

−5.36 (1.280)**

CDI total score

−2.45 (0.674)

−3.28 (0.682)

−0.83

0.335

−1.41 (0.681)*

−0.42 (0.703)

−3.36 (0.865)**

MASC total score

−4.99 (1.558)

−6.21 (1.575)

−1.21

0.540

−0.78 (1.432)

−0.55 (1.478)

−6.90 (2.299)**

  1. †From the Cochran-Mantel-Haenszel test controlling for pooled investigator sites; *p ≤ .05; **p ≤ .01; BPI Brief Pain Inventory, CDI Children’s Depression Inventory, CGI-S Clinical Global Impression-Severity, FDI Functional Disability Inventory, SE standard error, n number of patients, MASC multidimensional anxiety scale for children, PPQ Pediatric Pain Questionnaire. aAll patients who were randomized to duloxetine and had at least one non-missing post-baseline observation. bDefined as reduction in BPI average pain for open label and double blind+open label periods, only within group change was tested